Does Cosentyx Treat Ankylosing Spondylitis?
Yes, Cosentyx (secukinumab) is FDA-approved to treat active ankylosing spondylitis (AS) in adults.[1] It targets interleukin-17A (IL-17A), a protein driving inflammation in AS, reducing symptoms like back pain, stiffness, and spinal damage progression.
How Effective Is Cosentyx for AS?
In clinical trials like MEASURE 1 and 2, about 60% of patients on Cosentyx 150 mg achieved ASAS 20 response (20% symptom improvement) at week 16, compared to 28% on placebo.[2] Long-term data show sustained benefits up to 5 years, with many patients reaching low disease activity.[1]
Who Can Use Cosentyx for AS?
Adults with active AS who have not responded well to NSAIDs or TNF inhibitors. It's given as a 150 mg subcutaneous injection every 4 weeks after initial loading doses.[1] Not approved for children under 18 with AS.
Common Side Effects in AS Patients
Upper respiratory infections (15-20%), diarrhea (5-10%), and nasopharyngitis occur most often. Serious risks include infections like tuberculosis, inflammatory bowel disease flares, and rare allergic reactions. Monitor for these before starting.[1]
How Does Cosentyx Compare to Other AS Treatments?
| Treatment | Mechanism | ASAS 20 Response Rate (Week 16) | Dosing Frequency |
|-----------|-----------|---------------------------------|------------------|
| Cosentyx (IL-17 inhibitor) | Blocks IL-17A | ~60% | Monthly subQ |
| Humira (adalimumab, TNF inhibitor) | Blocks TNF | ~48-60% | Every 2 weeks subQ |
| Enbrel (etanercept, TNF inhibitor) | Blocks TNF | ~50-60% | Weekly subQ |
| Stelara (ustekinumab, IL-12/23 inhibitor) | Blocks IL-12/23 | ~40-50% | Every 8-12 weeks subQ |
Cosentyx often works in TNF non-responders and may better control structural damage in some cases.[2]
Cost and Access for AS Treatment
A 4-week supply costs $5,000-$6,000 without insurance in the US. Patient assistance programs from Novartis cover copays for eligible patients.[3] Biosimilars are not yet available.
When Does Cosentyx's Patent for AS Expire?
Key US patents on secukinumab expire in 2033-2034, with pediatric exclusivity potentially extending to 2035. No major challenges listed yet.[4]
[1]: FDA Label for Cosentyx
[2]: New England Journal of Medicine - MEASURE Trials
[3]: Novartis Patient Assistance
[4]: DrugPatentWatch.com - Cosentyx Patents